ABL Bio에이비엘바이오
298380 · KOSDAQ · ₩298380 · 에이비엘바이오
₩41,800▲ ₩950 (2.33%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — |
| Operating margin | −251.2% | −50.9% | −177.8% | −4.0% | 1.3% | −981.0% |
| Net margin | −229.4% | −47.6% | −166.2% | −4.0% | 4.8% | −816.9% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −56.8% | +137.6% | −49.0% | −2.6% | +1,162.2% | — |
| Operating income growth | −113.2% | +32.0% | −2,168.8% | −388.2% | +101.7% | — |
| Net income growth | −108.0% | +31.9% | −1,998.1% | −182.5% | +107.4% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −48.2% | −23.5% | −46.0% | −3.7% | 5.1% | −77.8% |
| Return on assets | −23.3% | −14.8% | −28.3% | −1.5% | 2.6% | −66.5% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 57.4% | 79.3% | 38.7% | 116.2% | 166.4% | 17.0% |
| Net debt to equity | −86.5% | −38.3% | — | — | — | −27.5% |
| Current ratio | 171.6% | 142.6% | 227.5% | 180.9% | 111.6% | 519.7% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: ABL Bio / 에이비엘바이오 / 298380 / KRX:298380
Source: KRX statistical information